# Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/tislelizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-or/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Shun Lü,Jie Wang,Yan Yu,Xinmin Yu,Yanping Hu,Xinghao Ai,Zhiyong Ma,Xingya Li,Wu Zhuang,Yunpeng Liu,Weidong Li,Jiuwei Cui,Dong Wang,Wangjun Liao,Jianying Zhou,Zhehai Wang,Yuping Sun,Xiusong Qiu,Jie Gao,Yuanyuan Bao,Liang Liang,Mengzhao Wang |
| Citations | 284 |
| DOI | 10.1016/j.jtho.2021.05.005 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | http://www.jto.org/article/S1556086421021766/pdf |
| OpenAlex ID | https://openalex.org/W3164993995 |
| PMID | 34033975 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Weidong Li](https://scholariq.org/researchers/weidong-li/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.